Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.18/5062
Título: 2015/16 I-MOVE/I-MOVE+ multicentre case control study in Europe: moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage mismatched influenza B among children
Autor: Kissling, Esther
Valenciano, Marta
Pozo, Francisco
Vilcu, Ana-Maria
Reuss, Annicka
Rizzo, Caterina
Larrauri, Amparo
Horváth, Judit Krisztina
Brytting, Mia
Domegan, Lisa
Korczyńska, Monika
Meijer, Adam
Machado, Ausenda
Ivanciuc, Alina
Višekruna Vučina, Vesna
van der Werf, Sylvie
Schweiger, Brunhilde
Bella, Antonino
Gherasim, Alin
Ferenczi, Annamária
Zakikhany, Katherina
O Donnell, Joan
Paradowska-Stankiewicz, Iwona
Dijkstra, Frederika
Guiomar, Raquel
Lazar, Mihaela
Kurečić Filipović, Sanja
Johansen, Kari
Moren, Alain
I-MOVE/I-MOVE+ study team
Palavras-chave: Case Control Study
Influenza
influenza Vaccine
Multicentre Study
Vaccine Effectiveness
Cuidados de Saúde
Efetividade da Vacina Antigripal
Vacina Antigripal
I-MOVE
I-MOVE+
Data: 10-Nov-2017
Citação: Influenza Other Respir Viruses. 2017 Nov 10. doi: 10.1111/irv.12520. [Epub ahead of print]
Resumo: Background:During the 2015/16 influenza season in Europe, the co-circulating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. Methods:We used the test negative design in a multicentre case–control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients ainfluenza Vaccinend a random sample of influenza positive swabs were sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. Results: We included 11,430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0–14, 15–64 and ≥65  years VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3-65.0), 41.4% (95%CI: 20.5-56.7) and 13.2% (95% CI: -38.0-45.3) respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95%CI: -4.1-56.7). Among those aged 0–14, 15–64 and ≥65 years VE against influenza B was -47.6% (95%CI: -124.9-3.1), 27.3% (95%CI: -4.6-49.4), and 9.3% (95%CI: -44.1-42.9) respectively. Conclusions: VE against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65  years. VE against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection are needed to understand the VE results against influenza B in the context of a mismatched vaccine.
Descrição: I-MOVE/I-MOVE+ study team - Portugal: Verónica Gomez, Ana Paula Rodrigues, Baltazar Nunes (Departamento de Epidemiologia, Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal); Pedro Pechirra, Paula Cristóvão, Patrícia Conde, Inês Costa (Departamento de Doenças Infeciosas, Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal).
Peer review: yes
URI: http://hdl.handle.net/10400.18/5062
DOI: 10.1111/irv.12520
ISSN: 1750-2640
Versão do Editor: http://onlinelibrary.wiley.com/doi/10.1111/irv.12520/abstract
Aparece nas colecções:DDI - Artigos em revistas internacionais
DEP - Artigos em revistas internacionais

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Kissling_et_al-2017-Influenza_and_Other_Respiratory_Viruses.pdf1,61 MBAdobe PDFVer/Abrir


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.